Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Hierarchy in Somatic Mutations Detected in Circulating and Tissue-Resident Follicular Lymphoma Precursors before Clinical Diagnosis

Joseph G Schroers-Martin, MD, Florian Scherer, MD, Joanne Soo, BS, David M. Kurtz, MD, Chih Long Liu, PhD, Henning Stehr, PhD, Agnès Bru, Yasodha Natkunam, MD PhD, Maximilian Diehn, MD PhD, Bertrand Nadel, PhD, Sandrine Roulland, PhD, Ash A. Alizadeh, MDPhD

Blood (2017) 130 (Supplement 1): 308.

https://doi.org/10.1182/blood.V130.Suppl_1.308.308

Published: 2017

Journal Articles

High-Resolution Analysis of the Relationship Between Dose and Molecular Response in CP-CML Patients Treated with Ponatinib or Imatinib

Justin R. Pritchard, Stephanie Lustgarten, Graeme Hodgson, Michele Baccarani, MD, Jorge E. Cortes, MD, Michael W. Deininger, Francois Guilhot, Andreas Hochhaus, MD, Timothy P. Hughes, Neil P. Shah, Moshe Talpaz, Tim Clackson, Frank G. Haluska, Ronald Knickerbocker, Victor M. Rivera

Blood (2014) 124 (21): 3153.

https://doi.org/10.1182/blood.V124.21.3153.3153

Published: 2014

Journal Articles

Characteristics and Outcomes of Unselected Adolescents and Young Adults Patients with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era

Stéphanie Bernardin, Franck E. Nicolini, MD PhD, Delphine Rea, MD PhD, Mael Haiblig, MD, Martine Gardembas, MD, Gabriel Etienne, MD PhD, P Cony-Makhoul, MD, Martine Escoffre-Barbe, MD, Stephane Giraudier, Agnes Guerci-Bresler, MD PhD, Valérie Coiteux, MD, Marc G Berger, MD PhD Professor, Lydia Roy, MD, Anne Corby, MD, Pierre-Simon Rohrlich, MDPhD, Françoise Huguet, MD, Laurence Legros, MD PhD

Blood (2014) 124 (21): 1803.

https://doi.org/10.1182/blood.V124.21.1803.1803

Published: 2014

Journal Articles

Insights into Relationships Between Serum Ferritin and Liver Iron Concentration Trends during 12 Months of Iron Chelation Therapy with Deferasirox – a Post-Hoc Analysis from the Epic Study

John B Porter, MD, Mohsen Elalfy, MD, Ali T Taher, MD, Lee Lee Chan, MD, Szu-Hee Lee, MD, Pranee Sutcharitchan, MD, Yesim Aydinok, MD, Subhashish Chakravarty, PhD, Ali El-Ali, MD, Amal El-Beshlawy, MD/Professor

Blood (2014) 124 (21): 52.

https://doi.org/10.1182/blood.V124.21.52.52

Published: 2014

Journal Articles

The EPIC Study: A Clinical Trial To Assess Whether Early Low Dose Prophylaxis In The Absence Of Immunological Danger Signals Reduces Inhibitor Incidence In Previously Untreated Patients (PUPs) With Hemophilia A

Guenter Auerswald, MD, Karin Kurnik, MD, Jan Blatny, MD, PhD, Armin J Reininger, MD

Blood (2013) 122 (21): 576.

https://doi.org/10.1182/blood.V122.21.576.576

Published: 2013

Journal Articles

Haemopoietic Improvement Following Iron Chelation for Transfusional Haemosiderosis in Patients with Haematopoietic Neoplasia and Aplastic Anaemia: An Observational Study

Stephen Opat, MBBS(Hons) FRACP FRCPA, Robert Bird, MD, Cecily J Forsyth, FRACP, FRCPA, Jeffrey Szer, MBBS, FRACP, Constantine S. Tam, MBBS, FRACP, FRCPA, Penelope Motum, MB BS PhD FRACP FRCPA, Mark A. Bentley, MBBS FRCPA FRACP

Blood (2011) 118 (21): 5050.

https://doi.org/10.1182/blood.V118.21.5050.5050

Published: 2011

Journal Articles

High Rate of Erythroid Response During Iron Chelation Therapy in a Cohort of 105 Patients Affected by Hematologic Malignancies with Transfusional Iron Overload: An Italian Multicenter Retrospective Study

Daniela Cilloni, MD, PhD, Emanuela Messa, Lucia Biale, MD, Margherita Bonferroni, MD, Flavia Salvi, MD, Monia Lunghi, M.D., Bernardino Allione, Dario Ferrero, Roberto Freilone, MD, Alessandro Levis, MD, Giuseppe Saglio

Blood (2011) 118 (21): 611.

https://doi.org/10.1182/blood.V118.21.611.611

Published: 2011

Journal Articles

Geographical Differences In Transfusion and Iron Chelation Practices In 1558 Patients with Transfusion-Dependent Anemias

Vip Viprakasit, MD, DPhil, Norbert Gattermann, MD, Jong Wook Lee, MD, John B. Porter, MD, Ali Taher, MD, Dany Habr, MD, Bernard Roubert, PhD, Gabor Domokos, PhD, Maria Domenica Cappellini, MD

Blood (2010) 116 (21): 4272.

https://doi.org/10.1182/blood.V116.21.4272.4272

Published: 2010

Journal Articles

Hematologic Responses In Myelodysplastic Syndromes (MDS) Patients Treated with Deferasirox: An EPIC Post-Hoc Analysis Using International Working Group (IWG) 2006 Criteria

Norbert Gattermann, MD, Carlo Finelli, MD, Matteo Della Porta, MD, Pierre Fenaux, MD, PhD, Michael Stadler, MD, Agnès Guerci-Bresler, MD, Mathias Schmid, MD, Kerry Taylor, MD, Dominique Vassilieff, MD, Dany Habr, MD, Andrea Marcellari, MS, MT(ASCP), Bernard Roubert, PhD, Christian Rose, MD

Blood (2010) 116 (21): 2912.

https://doi.org/10.1182/blood.V116.21.2912.2912

Published: 2010

Journal Articles

Improved Patient Satisfaction, Adherence and Health-Related Quality of Life with Deferasirox (Exjade®) in β-Thalassemia Patients Previously Receiving Other Iron Chelation Therapies.

John B. Porter, Miranda Athanasiou-Metaxa, Donald K. Bowden, Jacques Troncy, Dany Habr, Gabor Domokos, Bernard Roubert, Diana Rofail, Adam Gater, Jean-François Baladi, M. Domenica Cappellini

Blood (2009) 114 (22): 2486.

https://doi.org/10.1182/blood.V114.22.2486.2486

Published: 2009

Journal Articles

Correlation Between Decreased Serum Ferritin and Improved Liver Transaminases During Deferasirox (Exjade®) Treatment in Iron-Overloaded Patients with Myelodysplastic Syndromes.

Norbert Gattermann, Mathias Schmid, Agnès Guerci-Bresler, Matteo Della Porta, Kerry Taylor, Dany Habr, Gabor Domokos, Bernard Roubert, Pierre Fenaux

Blood (2009) 114 (22): 3803.

https://doi.org/10.1182/blood.V114.22.3803.3803

Published: 2009

Journal Articles

Deferasirox (Exjade®) Is Effective and Well Tolerated in Chelation-Naive and Previously Chelated Patients with Transfusion-Dependent Myelodysplastic Syndromes (MDS).

Mathias Schmid, Agnès Guerci-Bresler, Matteo Della Porta, Kerry Taylor, Dany Habr, Gabor Domokos, Bernard Roubert, Christian Rose, Norbert Gattermann, MD, PhD

Blood (2009) 114 (22): 3806.

https://doi.org/10.1182/blood.V114.22.3806.3806

Published: 2009

Journal Articles

Improvement in Right Ventricular Function Following 1 Year of Deferasirox Therapy in Patients with β-Thalassemia.

Gillian Smith, Dudley J. Pennell, John B. Porter, M. Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Yesim Aydinok, Hishamshah Ibrahim, Chi-Kong Lee, Vip Viprakasit, Mohsen Saleh Elalfy, Antonis Kattamis, Dany Habr, Gabor Domokos, Abdel Hmissi, Ali Taher

Blood (2009) 114 (22): 5106.

https://doi.org/10.1182/blood.V114.22.5106.5106

Published: 2009

Journal Articles

Efficacy and Safety of 1 Year’s Treatment with Deferasirox (Exjade ® ): Assessment of Regularly Transfused Patients with Diamond-Blackfan Anemia Enrolled in the EPIC Study.

John B Porter, Gian Luca Forni, Photis Beris, Ali Taher, Dany Habr, Gabor Domokos, Abdel Hmissi, Maria Domenica Cappellini

Blood (2008) 112 (11): 1048.

https://doi.org/10.1182/blood.V112.11.1048.1048

Published: 2008

Journal Articles

Satisfaction and Adherence Significantly Improves in Patients with β-Thalassemia and Myelodysplastic Syndromes Treated with Deferasirox (Exjade ® )

John B Porter, Donald Bowden, Arnold Ganser, Gabor Domokos, Diana Rofail, Jean-François Baladi, Maria Domenica Cappellini

Blood (2008) 112 (11): 1306.

https://doi.org/10.1182/blood.V112.11.1306.1306

Published: 2008

Journal Articles

Improved Health-Related Quality of Life in Patients with Hematological Disorders Receiving Deferasirox (Exjade ® )

John B Porter, Donald Bowden, Arnold Ganser, Gabor Domokos, Adam Gater, Jean-François Baladi, Maria Domenica Cappellini

Blood (2008) 112 (11): 1307.

https://doi.org/10.1182/blood.V112.11.1307.1307

Published: 2008

Journal Articles

Deferasirox Efficacy and Safety for the Treatment of Transfusion- Dependent Iron Overload in Patients with a Range of Rare Anemias.

John B Porter, Kai-Hsin Lin, Dany Habr, Gabor Domokos, Abdel Hmissi, Swee Lay Thein

Blood (2008) 112 (11): 1419.

https://doi.org/10.1182/blood.V112.11.1419.1419

Published: 2008

Journal Articles

Clinical BCR-ABL Peptide Vaccination in Chronic Myeloid Leukaemia: Results of the EPIC Study.

Jose M. Rojas, Katy Knight, Li-Hui Wang, Richard E. Clark

Blood (2006) 108 (11): 2197.

https://doi.org/10.1182/blood.V108.11.2197.2197

Published: 2006

NARROW

Hierarchy in Somatic Mutations Detected in Circulating and Tissue-Resident Follicular Lymphoma Precursors before Clinical Diagnosis

High-Resolution Analysis of the Relationship Between Dose and Molecular Response in CP-CML Patients Treated with Ponatinib or Imatinib

Characteristics and Outcomes of Unselected Adolescents and Young Adults Patients with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era

Insights into Relationships Between Serum Ferritin and Liver Iron Concentration Trends during 12 Months of Iron Chelation Therapy with Deferasirox – a Post-Hoc Analysis from the Epic Study

The EPIC Study: A Clinical Trial To Assess Whether Early Low Dose Prophylaxis In The Absence Of Immunological Danger Signals Reduces Inhibitor Incidence In Previously Untreated Patients (PUPs) With Hemophilia A

Haemopoietic Improvement Following Iron Chelation for Transfusional Haemosiderosis in Patients with Haematopoietic Neoplasia and Aplastic Anaemia: An Observational Study

High Rate of Erythroid Response During Iron Chelation Therapy in a Cohort of 105 Patients Affected by Hematologic Malignancies with Transfusional Iron Overload: An Italian Multicenter Retrospective Study

Geographical Differences In Transfusion and Iron Chelation Practices In 1558 Patients with Transfusion-Dependent Anemias

Hematologic Responses In Myelodysplastic Syndromes (MDS) Patients Treated with Deferasirox: An EPIC Post-Hoc Analysis Using International Working Group (IWG) 2006 Criteria

Improved Patient Satisfaction, Adherence and Health-Related Quality of Life with Deferasirox (Exjade®) in β-Thalassemia Patients Previously Receiving Other Iron Chelation Therapies.

Correlation Between Decreased Serum Ferritin and Improved Liver Transaminases During Deferasirox (Exjade®) Treatment in Iron-Overloaded Patients with Myelodysplastic Syndromes.

Deferasirox (Exjade®) Is Effective and Well Tolerated in Chelation-Naive and Previously Chelated Patients with Transfusion-Dependent Myelodysplastic Syndromes (MDS).

Improvement in Right Ventricular Function Following 1 Year of Deferasirox Therapy in Patients with β-Thalassemia.

Efficacy and Safety of 1 Year’s Treatment with Deferasirox (Exjade ® ): Assessment of Regularly Transfused Patients with Diamond-Blackfan Anemia Enrolled in the EPIC Study.

Satisfaction and Adherence Significantly Improves in Patients with β-Thalassemia and Myelodysplastic Syndromes Treated with Deferasirox (Exjade ® )

Improved Health-Related Quality of Life in Patients with Hematological Disorders Receiving Deferasirox (Exjade ® )

Deferasirox Efficacy and Safety for the Treatment of Transfusion- Dependent Iron Overload in Patients with a Range of Rare Anemias.

Clinical BCR-ABL Peptide Vaccination in Chronic Myeloid Leukaemia: Results of the EPIC Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only